These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 15183865

  • 21. The clinical significance of macrolide-resistant Streptococcus pneumoniae: it's all relative.
    Nuermberger E, Bishai WR.
    Clin Infect Dis; 2004 Jan 01; 38(1):99-103. PubMed ID: 14679455
    [Abstract] [Full Text] [Related]

  • 22. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR.
    Clin Infect Dis; 2002 Sep 01; 35(5):565-9. PubMed ID: 12173130
    [No Abstract] [Full Text] [Related]

  • 23. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP, Martinez FJ.
    Clin Infect Dis; 2002 Mar 01; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [Abstract] [Full Text] [Related]

  • 24. Resistance among Streptococcus pneumoniae: Implications for drug selection.
    Appelbaum PC.
    Clin Infect Dis; 2002 Jun 15; 34(12):1613-20. PubMed ID: 12032897
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG.
    Diagn Microbiol Infect Dis; 2008 Sep 15; 62(1):99-101. PubMed ID: 18583085
    [Abstract] [Full Text] [Related]

  • 26. In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS).
    Wierzbowski AK, Karlowsky JA, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2009 Mar 15; 63(3):620-2. PubMed ID: 19151038
    [No Abstract] [Full Text] [Related]

  • 27. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Yokota S, Ohkoshi Y, Fujii N.
    Diagn Microbiol Infect Dis; 2009 Sep 15; 65(1):76-80. PubMed ID: 19679241
    [Abstract] [Full Text] [Related]

  • 28. Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates.
    Adam HJ, Schurek KN, Decorby MR, Weshnoweski B, Vashisht R, Karlowsky K, Hoban DJ, Zhanel GG.
    J Antimicrob Chemother; 2006 Jul 15; 58(1):202-4. PubMed ID: 16636082
    [Abstract] [Full Text] [Related]

  • 29. Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital.
    Bonofiglio L, Ojeda MI, de Mier C, Vay C, Famiglietti A, Gutkind G, Mollerach M.
    Int J Antimicrob Agents; 2005 Mar 15; 25(3):260-3. PubMed ID: 15737523
    [Abstract] [Full Text] [Related]

  • 30. Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).
    Hawser SP.
    J Infect; 2010 Apr 15; 60(4):306-8. PubMed ID: 20144899
    [No Abstract] [Full Text] [Related]

  • 31. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, Holmes PW, Christiansen KJ, Waterer GW, Pierce RJ, Mayall BC, Armstrong JG, Catton MG, Nimmo GR, Johnson B, Hooy M, Grayson ML, Australian CAP Study Collaboration.
    Clin Infect Dis; 2008 May 15; 46(10):1513-21. PubMed ID: 18419484
    [Abstract] [Full Text] [Related]

  • 32. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M.
    Dtsch Med Wochenschr; 2003 May 09; 128(19):1071. PubMed ID: 12736860
    [No Abstract] [Full Text] [Related]

  • 33. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study.
    Farrell DJ, File TM, Jenkins SG.
    J Clin Microbiol; 2007 Feb 09; 45(2):290-3. PubMed ID: 17093012
    [Abstract] [Full Text] [Related]

  • 34. Distribution across the USA of macrolide resistance and macrolide resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with respiratory tract infections: PROTEKT US 2001-2002.
    Farrell DJ, Jenkins SG.
    J Antimicrob Chemother; 2004 Aug 09; 54 Suppl 1():i17-22. PubMed ID: 15265832
    [Abstract] [Full Text] [Related]

  • 35. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.
    Arifeen SE, Saha SK, Rahman S, Rahman KM, Rahman SM, Bari S, Naheed A, Mannan I, Seraji MH, Ahmed NU, Hassan MS, Huda N, Siddik AU, Quasem I, Islam M, Fatima K, Al-Emran H, Brooks WA, Baqui AH, Breiman RF, Sack D, Luby SP.
    Clin Infect Dis; 2009 Mar 01; 48 Suppl 2():S103-13. PubMed ID: 19191605
    [Abstract] [Full Text] [Related]

  • 36. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
    Low DE.
    Infect Dis Clin North Am; 2013 Mar 01; 27(1):87-97. PubMed ID: 23398867
    [Abstract] [Full Text] [Related]

  • 37. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov 01; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 38. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ, Zhanel GG.
    Expert Rev Anti Infect Ther; 2006 Dec 01; 4(6):973-80. PubMed ID: 17181414
    [Abstract] [Full Text] [Related]

  • 39. [Acute community-acquired pneumonia. A review of clinical trials].
    Chidiac C.
    Med Mal Infect; 2006 Dec 01; 36(11-12):650-66. PubMed ID: 16876363
    [Abstract] [Full Text] [Related]

  • 40. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May 01; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.